FDA-Approved Cemiplimab-rwlc is Effective in the Treatment of Patients with Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) and Patients with Locally Advanced CSCC Who Are Not Candidates for Curative Surgery or Curative Radiation

By DocWire News Editors - Last Updated: August 1, 2023

MarkAlain Déry, DO, MPH, FACOINeurodivergent | May 8, 2025

1 in 31 U.S. kids are diagnosed with autism—what’s behind the rise? Noise Filter breaks it down, myths and all.

Pranav Garimella, MBBS, MPHNephrology Times | May 7, 2025

Dr. Pranav Garimella, CMO of the American Kidney Fund, discussed AMKD awareness and the importance of APOL1 gene variants.

MarkAlain Déry, DO, MPH, FACOIInfectious Disease | May 5, 2025

The NoiseFilter team expresses deep concern over policy changes to vaccine strategy following RFK Jr's appointment.

Joel Topf spoke with Mini Michael about the ILLUMINATE-B study of lumasiran for PH1 in infants and young children.

Richard Lafayette, MDIgA Nephropathy | May 1, 2025

We spoke with ALIGN study investigator Richard Lafayette, MD, upon the FDA's accelerated approval of atrasentan for IgAN.

Related Posts